Want to see ELVN full AI Analyst Report?
Enliven Therapeutics (ELVN) Ownership - Who Owns Enliven Therapeutics?
Enliven Therapeutics (ELVN) Ownership Overview
- 22.50% Insiders
- 23.44% Mutual Funds
- 1.87% Other Institutional Investors
- 12.01% ETFs
- 40.18% Public Companies and Individual Investors
The ownership structure of Enliven Therapeutics (ELVN) stock is a mix of institutional, retail, and individual investors. Approximately 37.32% of the company’s stock is owned by Institutional Investors, 22.50% is owned by Insiders, and 40.18% is owned by Public Companies and Individual Investors.
The ownership structure of Enliven Therapeutics (ELVN) stock is a mix of institutional, retail, and individual investors. Approximately 37.32% of the company’s stock is owned by Institutional Investors, 22.50% is owned by Insiders, and 40.18% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jun 23, 2026 | Orbimed Advisors Llc | $39,014,046 | |
| Jun 16, 2026 | Orbimed Advisors Llc | $12,668,988 | |
| Mar 09, 2026 | Benjamin Hohl | $295,800 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Jun 30, 2026 | Blackstone Inc. | $10,949,008 | |
| Jun 30, 2026 | Woodline Partners Lp | $17,617,457 | |
| Jun 30, 2026 | $221,254,978 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Rishi Gupta | 7,663,349 | Insider | 10.46% | 339,103,193 |
| Orbimed Advisors Llc | 6,555,102 | Insider | 8.95% | 290,063,264 |
| BlackRock, Inc. | 4,359,704 | Institution | 5.95% | 192,916,902 |
| Vanguard | 3,432,964 | Institution | 4.69% | 151,908,657 |
| Ishares | 3,080,937 | Institution | 4.20% | 136,331,462 |
| Fidelity Securities Fund | 2,827,132 | Institution | 3.86% | 125,100,591 |
| Vanguard Index Funds | 2,508,047 | Institution | 3.42% | 110,981,080 |
| Fidelity Select Portfolios | 2,041,962 | Institution | 2.79% | 90,356,819 |
| Peter Harwin | 1,855,644 | Institution | 2.53% | 82,112,247 |
| Fidelity Advisor Series Vii | 1,171,368 | Institution | 1.60% | 51,833,034 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Securities Fund | 2,827,132 | Institution | 3.86% | 125,100,591 |
| Vanguard Index Funds | 2,508,047 | Institution | 3.42% | 110,981,080 |
| Fidelity Select Portfolios | 2,041,962 | Institution | 2.79% | 90,356,819 |
| Fidelity Advisor Series Vii | 1,171,368 | Institution | 1.60% | 51,833,034 |
| T. Rowe Price New Horizons Fund, Inc. | 807,329 | Institution | 1.10% | 35,724,308 |
| Fidelity Concord Street Trust | 786,959 | Institution | 1.07% | 34,822,936 |
| Fidelity Rutland Square Trust Ii | 737,595 | Institution | 1.01% | 32,638,579 |
| Fidelity Salem Street Trust | 652,854 | Institution | 0.89% | 28,888,790 |
| T. Rowe Price Health Sciences Fund, Inc. | 647,454 | Institution | 0.88% | 28,649,840 |
| Fidelity Capital Trust | 579,691 | Institution | 0.79% | 25,651,327 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard, VTI ETF | 2,106,121 | Institution | 2.87% | 96,544,587 |
| iShares, IWM ETF | 1,484,334 | Institution | 2.03% | 66,913,777 |
| Vanguard, VXF ETF | 719,608 | Institution | 0.98% | 32,986,831 |
| iShares, IWO ETF | 547,971 | Institution | 0.75% | 24,247,717 |
| iShares, IBB ETF | 473,644 | Institution | 0.65% | 20,958,747 |
| DFA, DFAS ETF | 353,098 | Institution | 0.48% | 15,917,658 |
| Schwab, SCHA ETF | 338,553 | Institution | 0.46% | 15,261,969 |
| Vanguard, VTWO ETF | 338,463 | Institution | 0.46% | 15,515,144 |
| iShares, IHE ETF | 215,440 | Institution | 0.29% | 9,533,220 |
| SPDR, XPH ETF | 156,493 | Institution | 0.21% | 7,054,704 |
FAQ
Who Owns Enliven Therapeutics (ELVN)?
According to the latest TipRanks data, approximately 37.32% of the company's stock is held by institutional investors, 22.50% is held by insiders, and 40.18% is held by public companies and individual investors.
What percentage of Enliven Therapeutics (ELVN) stock is held by institutional investors?
According to the latest TipRanks data, approximately 37.32% of Enliven Therapeutics (ELVN) stock is held by institutional investors: 23.44% by mutual funds, 12.01% by ETFs and 1.87% by other institutional investors.
What percentage of Enliven Therapeutics (ELVN) stock is held by retail investors?
According to the latest TipRanks data, approximately 40.18% of Enliven Therapeutics (ELVN) stock is held by public companies and individual investors.
Who owns the most shares of Enliven Therapeutics (ELVN)?
Rishi Gupta owns the most shares of Enliven Therapeutics (ELVN).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
